Global Somatostatin Analogs Market Report 2024

Somatostatin Analogs Global Market Report 2024 – By Type (Octreotide, Lanreotide, Pasireotide), By Treatment (Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments), By End User (Hospital, Pharmaceutical Companies) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Somatostatin Analogs Global Market Report 2023

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Somatostatin Analogs Market Definition And Segments

A somatostatin analog is a synthetic version of somatostatin that slows the production of hormones, such as serotonin and the growth hormone. It is used to reduce carcinoid syndrome symptoms, including diarrhea and skin flushing.

The main types of somatostatin analogs are octreotide, lanreotide, and pasireotide. Octreotide refers to a medication that blocks growth hormones like the naturally occurring somatostatin, which is used to treat certain forms of tumor-related diarrhea and flushing. These are used in acromegaly, Cushing’s syndrome, neuroendocrine tumors, carcinoid syndrome, and others, used by end users including hospitals and pharmaceutical companies.

The somatostatin analogs market covered in this report is segmented –

1) By Type: Octreotide, Lanreotide, Pasireotide

2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments

3) By End User: Hospital, Pharmaceutical Companies

The somatostatin analogs market size has grown strongly in recent years. It will grow from $6.23 billion in 2023 to $6.68 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased net incidence, advancements in oncology research, clinical efficacy in symptom management, expansion of indications, patient preference for long-acting formulations..

The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $8.67 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to continued rise in net incidence, research focus on rare diseases, development of combination therapies, advancements in personalized medicine, global health initiatives in cancer care.. Major trends in the forecast period include global aging population, healthcare infrastructure development in emerging markets, strategic collaborations and partnerships, pricing pressures and reimbursement challenges, technological integration in healthcare..

Surge In Incidence Propels Growth In The Somatostatin Analogs Market

The rise in the incidence of neuroendocrine tumors is expected to propel the growth of the somatostatin analogs market going forward. Neuroendocrine tumors refer to malignancies that start in specialized neuroendocrine cells. Analogs of somatostatin prevent the body from producing too many hormones. They decrease a neuroendocrine tumor's growth and reduce carcinoid disease symptoms. For instance, according to Cancer Australia, an Australia-based national government agency, in 2022, around 5,437 new cases of neuroendocrine tumors were diagnosed in Australia, and it was estimated that a person has a 1 in 55 risks of being diagnosed with neuroendocrine tumors by the age of 85. Therefore, the rise in the incidence of neuroendocrine tumors is driving the growth of the somatostatin analogs market.

Growing Aging Population Boost Somatostatin Analogs Market

The growing aging population market is expected to propel the growth of the somatostatin analogs market going forward. The aging population refers to a demographic shift characterized by a higher proportion or an increasing number of individuals in a society who are aged 65 years and older. The rise in the aging demographic correlates with a higher incidence of diseases that warrant the use of Somatostatin Analogs, driving the demand for these pharmaceuticals. For instance, in 2022, visual capitalist, a Canada based company creates and curates visual content focused on latest trends, there were 771 million people aged 65+ years globally, accounting for almost 10% of the world’s population. Therefore, the growing aging population is driving the growth of the somatostatin analogs market.

Major companies operating in the somatostatin analogs market report are Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma PLC, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Dauntless Pharmaceuticals Inc., Bayer Aktiengesellschaft, Mylan N.V., Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma PLC, Ipsen Pharma SA, Fresenius Kabi AG, Biodexa Pharmaceuticals PLC, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Viatris Inc., AstraZeneca PLC, Johnson & Johnson, Moderna Inc., HRA Pharma, Genentech Inc., OctreoPharm Sciences GmbH

Innovative Drug Therapies For Cushing's Syndrome In The Somatostatin Analog Market

Innovation of novel drug therapies is a key trend gaining popularity in the somatostatin analog market. Major companies operating in the somatostatin analogs market are developing innovative drug therapies to strengthen their position in the market. For instance, in December 2021, Xeris Biopharma Holdings, Inc., a US-based biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, announced the U.S. Food and Drug Administration (FDA) approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. With this approval, Xeris’ experienced endocrinology-focused commercial organization can begin rapidly working to help address the needs of Cushing’s syndrome patients in the U.S. who are treated with prescription therapy.

Groundbreaking Generic Lanreotide Expanding Treatment Options In The Somatostatin Analogs Market

Product innovation is a key trend gaining popularity in the somatostatin analogs market. Major companies in the somatostatin analogs market are launching innovative products such as Lanreotide to sustain their position in the somatostatin analogs market. Lanreotide is a medication that belongs to a class of drugs known as somatostatin analogs. For instance, in July 2021, ADVANZ PHARMA, an India based specialty pharmaceutical company with a strategic focus on complex medicines in Europe, announced the launch of MYTOLAC (lanreotide) in Germany, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumors and symptoms associated with neuroendocrine tumors.

Amryt Pharma Enhances Portfolio Acquisition Of Chiasma Inc

In August 2021, Amryt Pharma PLC, a UK-based specialty pharmaceutical company, acquired Chiasma, Inc. for $330 million. This acquisition expands the potential of Mycapssa in patients with carcinoid symptoms stemming from neuroendocrine tumors (""NET""), where the commercial opportunity is significant. Chiasma Inc. is a US-based biopharmaceutical company that develops pharmaceutical products for treating acromegaly and hormonal disorders.

North America was the largest region in the global somatostatin analogs treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the somatostatin analogs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The somatostatin analogs market consists of sales of sandostatin, sandostatin lar, olatuton, somatuline LA, and somatuline autogel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The somatostatin analogs market research report is one of a series of new reports from The Business Research Company that provides somatostatin analogs market statistics, including the somatostatin analogs industry global market size, regional shares, competitors with a somatostatin analogs market share, detailed somatostatin analogs market segments, market trends, and opportunities, and any further data you may need to thrive in the somatostatin analogs industry. This somatostatin analogs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Somatostatin Analogs Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $6.68 billion
Revenue Forecast In 2033 $8.67 billion
Growth Rate CAGR of 6.7% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Octreotide, Lanreotide, Pasireotide
2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments
3) By End User: Hospital, Pharmaceutical Companies
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Novartis International AG; Pfizer Inc.; Sun Pharmaceutical Industries Limited; Midatech Pharma plc; Crinetics Pharmaceuticals Inc.; Peptron Inc.; Teva Pharmaceutical Industries Ltd.; Camurus AB; Dauntless Pharmaceuticals Inc.; Bayer Aktiengesellschaft; Mylan N.V.; Cadila Healthcare Limited; Amneal Pharmaceuticals Inc.; Recordati S.p.A.; Amryt Pharma plc; Ipsen Pharma SA; Fresenius Kabi AG; Biodexa Pharmaceuticals PLC; Chiasma Inc.; Merck KGaA; Sanofi S.A.; Sandoz International GmbH; Takeda Pharmaceutical Company Limited; Thermo Fisher Scientific Inc.; Viatris Inc.; AstraZeneca plc; Johnson & Johnson; Moderna Inc.; HRA Pharma; Genentech Inc.; OctreoPharm Sciences GmbH
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Somatostatin Analogs Market Characteristics

    3. Somatostatin Analogs Market Trends And Strategies

    4. Somatostatin Analogs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Somatostatin Analogs Market Size and Growth

    5.1. Global Somatostatin Analogs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Somatostatin Analogs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Somatostatin Analogs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Somatostatin Analogs Market Segmentation

    6.1. Global Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Octreotide

    Lanreotide

    Pasireotide

    6.2. Global Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Acromegaly

    Cushing’s Syndrome

    Neuroendocrine Tumors

    Carcinoid Syndrome

    Other Treatments

    6.3. Global Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital

    Pharmaceutical Companies

    7. Somatostatin Analogs Market Regional And Country Analysis

    7.1. Global Somatostatin Analogs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Somatostatin Analogs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Somatostatin Analogs Market

    8.1. Asia-Pacific Somatostatin Analogs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Somatostatin Analogs Market

    9.1. China Somatostatin Analogs Market Overview

    9.2. China Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Somatostatin Analogs Market

    10.1. India Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Somatostatin Analogs Market

    11.1. Japan Somatostatin Analogs Market Overview

    11.2. Japan Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Somatostatin Analogs Market

    12.1. Australia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Somatostatin Analogs Market

    13.1. Indonesia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Somatostatin Analogs Market

    14.1. South Korea Somatostatin Analogs Market Overview

    14.2. South Korea Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Somatostatin Analogs Market

    15.1. Western Europe Somatostatin Analogs Market Overview

    15.2. Western Europe Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Somatostatin Analogs Market

    16.1. UK Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Somatostatin Analogs Market

    17.1. Germany Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Somatostatin Analogs Market

    18.5. France Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Somatostatin Analogs Market

    19.9. Italy Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Somatostatin Analogs Market

    20.13. Spain Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Somatostatin Analogs Market

    21.1. Eastern Europe Somatostatin Analogs Market Overview

    21.2. Eastern Europe Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Somatostatin Analogs Market

    22.1. Russia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Somatostatin Analogs Market

    23.1. North America Somatostatin Analogs Market Overview

    23.2. North America Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Somatostatin Analogs Market

    24.1. USA Somatostatin Analogs Market Overview

    24.2. USA Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Somatostatin Analogs Market

    25.1. Canada Somatostatin Analogs Market Overview

    25.2. Canada Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Somatostatin Analogs Market

    26.1. South America Somatostatin Analogs Market Overview

    26.2. South America Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Somatostatin Analogs Market

    27.1. Brazil Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Somatostatin Analogs Market

    28.1. Middle East Somatostatin Analogs Market Overview

    28.2. Middle East Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Somatostatin Analogs Market

    29.1. Africa Somatostatin Analogs Market Overview

    29.2. Africa Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Somatostatin Analogs Market Competitive Landscape And Company Profiles

    30.1. Somatostatin Analogs Market Competitive Landscape

    30.2. Somatostatin Analogs Market Company Profiles

    30.2.1. Novartis International AG

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Pfizer Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Sun Pharmaceutical Industries Limited

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Midatech Pharma plc

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Crinetics Pharmaceuticals Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Somatostatin Analogs Market Competitive Benchmarking

    32. Global Somatostatin Analogs Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Somatostatin Analogs Market

    34. Somatostatin Analogs Market Future Outlook and Potential Analysis

    34.1 Somatostatin Analogs Market In 2028 - Countries Offering Most New Opportunities

    34.2 Somatostatin Analogs Market In 2028 - Segments Offering Most New Opportunities

    34.3 Somatostatin Analogs Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Somatostatin Analogs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Somatostatin Analogs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Novartis International AG Financial Performance
  • Table 75: Pfizer Inc. Financial Performance
  • Table 76: Sun Pharmaceutical Industries Limited Financial Performance
  • Table 77: Midatech Pharma plc Financial Performance
  • Table 78: Crinetics Pharmaceuticals Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Somatostatin Analogs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Somatostatin Analogs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Novartis International AG Financial Performance
  • Figure 75: Pfizer Inc. Financial Performance
  • Figure 76: Sun Pharmaceutical Industries Limited Financial Performance
  • Figure 77: Midatech Pharma plc Financial Performance
  • Figure 78: Crinetics Pharmaceuticals Inc. Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
Brain Tumor Drugs Global Market Report 2024 – By Drugs (Temozolomide, Bevacizumab, Other Drugs), By End User (Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Tumor Ablation Therapy Devices Global Market Report 2024 – By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, Other Technologies), By Treatment (Surgical, Laparoscopic, Percutaneous), By Application (Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Other Applications), By End User (Hospitals, Oncology Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Tumor Embolization Devices Global Market Report 2024 – By Type (Radioembolic Agents, Non-radioactive Embolic Agents), By Application (Cancer Tumors, Noncancerous Tumors), By End User (Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Cancer Tumor Profiling Global Market Report 2024 – By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types ), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies), By Process Type (Genomics, Proteomics, Epigenetics, Metabolomics, Other Types), By Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Circulating Tumor Cells Global Market Report 2024 – By Product (Kits And Reagents, Blood Collection Tubes, Devices Or Systems), By Technology (CTC Enrichment, CTC Detection, CTC Analysis), By Specimen (Blood, Bone Marrow, Other Body Fluids), By Application (Clinical Or Liquid Biopsy, Research) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024 – By Product Type (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars ), By Route Of Administration (Subcutaneous Injection, Intravenous Injection ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies ), By Application (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Tumor Infiltrating Lymphocytes Global Market Report 2024 – By Anatomy (CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, FOXP3), By Component (T-Cells, B-Cells, Natural Killer Cells), By Application (Melanoma, Cervical Cancer, Ovarian Cancer, Other Applications), By End-User (Hospitals, Cancer Research Centers, Clinics) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Solid Tumor Cancer Treatment Global Market Report 2024 – By Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Surgical Procedures), By Application (Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Other Applications ), By End-Users (Hospitals, Research Institutes, Homecare) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the somatostatin analogs market?

A somatostatin analog is a synthetic version of somatostatin that slows the production of hormones, such as serotonin and the growth hormone. It is used to reduce carcinoid syndrome symptoms, including diarrhea and skin flushing. For further insights on the somatostatin analogs market, request a sample here

How will the somatostatin analogs market drivers and restraints affect the somatostatin analogs market dynamics? What forces will shape the somatostatin analogs industry going forward?

The somatostatin analogs market major growth driver - surge in incidence propels growth in the somatostatin analogs market. For further insights on the somatostatin analogs market, request a sample here

What is the forecast market size or the forecast market value of the somatostatin analogs market ?

The somatostatin analogs market size has grown strongly in recent years. It will grow from $6.23 billion in 2023 to $6.68 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased net incidence, advancements in oncology research, clinical efficacy in symptom management, expansion of indications, patient preference for long-acting formulations.. The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $8.67 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to continued rise in net incidence, research focus on rare diseases, development of combination therapies, advancements in personalized medicine, global health initiatives in cancer care.. Major trends in the forecast period include global aging population, healthcare infrastructure development in emerging markets, strategic collaborations and partnerships, pricing pressures and reimbursement challenges, technological integration in healthcare.. For further insights on the somatostatin analogs market, request a sample here

How is the somatostatin analogs market segmented?

The somatostatin analogs market is segmented
1) By Type: Octreotide, Lanreotide, Pasireotide
2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments
3) By End User: Hospital, Pharmaceutical CompaniesFor further insights on the somatostatin analogs market, request a sample here

Which region has the largest share of the somatostatin analogs market? What are the other regions covered in the report?

North America was the largest region in the global somatostatin analogs treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the somatostatin analogs market, request a sample here.

Who are the major players in the somatostatin analogs market?

Major companies operating in the somatostatin analogs market report are Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Dauntless Pharmaceuticals Inc., Bayer Aktiengesellschaft, Mylan N.V., Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Biodexa Pharmaceuticals PLC, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Viatris Inc., AstraZeneca plc, Johnson & Johnson, Moderna Inc., HRA Pharma, Genentech Inc., OctreoPharm Sciences GmbH For further insights on the somatostatin analogs market, request a sample here.

What are the key trends in the somatostatin analogs market?

Major trend in the somatostatin analogs market - innovative drug therapies for cushing’s syndrome in the somatostatin analog market. For further insights on the somatostatin analogs market, request a sample here.

What are the major opportunities in the somatostatin analogs market? What are the strategies for the somatostatin analogs market?

For detailed insights on the major opportunities and strategies in the somatostatin analogs market, request a sample here.

How does the somatostatin analogs market relate to the overall economy and other similar markets?

For detailed insights on somatostatin analogs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the somatostatin analogs industry?

For detailed insights on the mergers and acquisitions in the somatostatin analogs industry, request a sample here.

What are the key dynamics influencing the somatostatin analogs market growth? SWOT analysis of the somatostatin analogs market.

For detailed insights on the key dynamics influencing the somatostatin analogs market growth and SWOT analysis of the somatostatin analogs industry, request a sample here.